Clinical features of and severity risk factors for COVID-19 in adults during the predominance of SARS-CoV-2 XBB variants in Okinawa, Japan
Open Access
- 31 October 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0309808
Abstract
Background and objective: Since 2023, COVID-19 induced by SARS-CoV-2 XBB variants have been a global epidemic. The XBB variant-induced epidemic was largest in the Okinawa Prefecture among areas in Japan, and healthcare institutions have been burdened by increased COVID-19 hospitalizations. This study aimed to evaluate the clinical features of XBB variant-induced COVID-19 and risk factors for severe COVID-19. Methods: This retrospective study included adult patients hospitalized for COVID-19 between May and July 2023 at four tertiary medical institutions in Okinawa, Japan. Patients with bacterial infection-related complications were excluded. According to oxygen supplementation and intensive care unit admission, patients were divided into two groups, mild and severe. Patient backgrounds, symptoms, and outcomes were compared between both groups, and the risk factors for severe COVID-19 were analyzed using a multivariate logistic regression model. Results: In total of 367 patients included, the median age was 75 years, with 18.5% classified into the severe group. The all-cause mortality rate was 4.9%. Patients in the severe group were more older, had more underlying diseases, and had a higher mortality rate (13.2%) than those in the mild group (3.0%). Multivariate logistic regression analysis showed that diabetes mellitus was an independent risk factor for severe COVID-19 (95% confidence interval [CI], 1.002–3.772), whereas bivalent omicron booster vaccination was an independent factor for less severe COVID-19 (95% CI, 0.203–0.862). Conclusion: This study implies that assessing risk factors in older adults is particularly important in the era of omicron variants.Keywords
Funding Information
- A research grant of Advanced Medical Research Center, Faculty of Medicine, University of the Ryukyus, Japan.
This publication has 26 references indexed in Scilit:
- Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patientsMed, 2023
- Comparison of XBB and BA.5.2: Differences in Clinical Characteristics and Disease OutcomesArchivos de Bronconeumología, 2023
- Investigating the role of glycans in Omicron sub-lineages XBB.1.5 and XBB.1.16 binding to host receptor using molecular dynamics and binding free energy calculationsJournal of Computer-Aided Molecular Design, 2023
- Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmissionClinical Microbiology and Infection, 2023
- Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysisJournal of Clinical Virology, 2023
- Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort studyThe Lancet Infectious Diseases, 2023
- Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolateThe Lancet Infectious Diseases, 2023
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- Risk and Protective Factors for COVID-19 Morbidity, Severity, and MortalityClinical Reviews in Allergy & Immunology, 2022
- Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19Diabetes Research and Clinical Practice, 2020